Astrazeneca (AZN) Other Operating Expenses (2009 - 2026)

Astrazeneca (AZN) has reported Other Operating Expenses for 18 consecutive years, with $189.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Operating Expenses rose 67.26% year-over-year to $189.0 million; the TTM figure through Mar 2026 stood at $457.0 million (up 53.36% YoY), while the FY2025 annual figure was $381.0 million, up 51.19% from the prior year.
• Other Operating Expenses came in at $189.0 million for Q1 2026 at Astrazeneca, up from $100.0 million in the prior quarter.
• The five-year high for Other Operating Expenses was $784.0 million in Q2 2023, with the low at $25.0 million in Q3 2024.
• Average Other Operating Expenses over 5 years is $157.4 million, with a median of $100.0 million recorded in 2024.
• Across the five-year window, Other Operating Expenses jumped 542.62% in 2023 and sank 92.35% in 2024, its largest moves.
• Year by year, Other Operating Expenses stood at $189.0 million in 2022, then sank by 43.39% to $107.0 million in 2023, then fell by 6.54% to $100.0 million in 2024, then changed by 0.0% to $100.0 million in 2025, then jumped by 89.0% to $189.0 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $189.0 million, $100.0 million, and $89.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.